If you thought the opioid crisis in America was winding down, you’re not alone…
For the last two years, the mainstream media has pretty much ignored this epidemic. They’re far too busy talking about mask mandates and vaccines.
But in the 12 months between June 2020 and 2021, more than 100,000 Americans quietly died from an opioid-related drug overdose. That’s double from the year before…
And another 700,000 are projected to die from opioids in the next decade. That will bring the total death toll to 1.4 million.1,2
All because Big Pharma wanted to make obscene amounts of money.3
For almost 30 years, the giant drug conglomerates turned America into one giant “pill mill.” They churned out 1 billion painkillers a year.4 They bribed thousands of doctors to push their poison.5
And their friends in the FDA gave them a license to kill.6
Today, an estimated three million people in the country continue to suffer from a crippling opioid addiction…
But Big Pharma isn’t finished making money off the crisis.
I guess the $12 trillion they already made isn’t enough.7
Now, the same industry that got us into this catastrophe thinks they have the solution. And once again, their cronies at the FDA are supporting them all the way…
The Food and Drug Administration recently allowed a new CBD-based drug therapy for opioid addiction to move forward in clinical trials.
Pharma scientists say they’re “hopeful” that this new prescription will be the game changer we’ve been waiting for.
What they’re really hoping for is that it will make them a boatload of money… That way, they can profit from the very problem they created!
Nantheia ATL5, the name of the drug moving forward in clinical trials, is a liquid formula containing high levels of CBD.
So what makes their potential new drug
different from the CBD you can already take? Besides the outrageous price tag, you’d better believe they’ll charge.The only real difference is a delivery method they’ve patented. Their “liquid structure technology” promises to make CBD more absorbable.
But the technology to get CBD where it’s needed already exists. More on this in a moment. First, let’s see what makes CBD such a powerful tool in the fight against opioid addiction.
A placebo-controlled study published in the American Journal of Psychiatry indicated that CBD could reduce cravings for opioids. Patients who received CBD experienced fewer withdrawal symptoms, while those who received a placebo or no treatment saw no change.8
Two additional studies looked at what happened with opioid use after Congress legalized hemp and other cannabinoids. Both studies found that as more people turned to CBD, opioid use dropped dramatically.
And opioid-related deaths decreased by a whopping 35%.9
But even more important is the research that finds CBD can relieve even the most crippling pain and the inflammation that causes it. CBD alleviates pain and the sensation of pain by stimulating the reuptake of a pain-relieving neurotransmitter called adenosine. This boosts adenosine levels in the brain and inhibits pain sensations.
CBD may also block pain signals from reaching processing centers in the brain by binding to TPRV1, which is responsible for pain and inflammation.10,11,12
According to another study published in the European Journal of Internal Medicine, 20% of hemp oil users were able to quit taking opiates. 13
Maximize your body’s absorption of CBD
Big Pharma is hoping to cash in on a real problem with CBD – its lack of bioavailability. Many CBD users are indeed getting just a fraction of this healing herb’s benefits.
That’s because most CBD doesn’t reach its intended destination: the cell receptors that make up the body’s endocannabinoid system.
In fact, the most common kind of CBD delivery system — oil — can’t reach the cell membrane. That means you’re not getting all of the benefits of CBD.
I’ve discovered that an oral spray that uses nanotechnology is the most bioavailable. That’s because it’s a quicker, more direct route to the bloodstream and avoids the liver’s “first pass” effect, lowering CBD bioavailability.
In fact, nanotechnology gets 1,500% more CBD past your cell membranes.14
To get maximum benefit, spray the liquid under your tongue, hold it without talking for 60 seconds and then swallow.
Here are a couple more ways to increase absorption.
-
- Look for full-spectrum CBD. Terpenes are fatty oils found in the essential oils of almost all plants. They occur naturally in hemp and are extracted along with CBD and other compounds to create full-spectrum CBD products. These compounds work together and amplify each other’s benefits, a synergy known as the “entourage effect.” Terpenes increase CBD bioavailability and enhance the therapeutic effects of cannabinoids.
- Take it with healthy fats. CBD is a fat-soluble compound, meaning it dissolves in fats. This breaks CBD down into smaller molecules more easily absorbed by the body. One way to increase CBD’s bioavailability is to mix it with a healthy high-fat snack or meal. A recent study found that people who took CBD with high-fat foods increased their absorption up to 14 times more than those who took it on an empty stomach.15
To Your Good Health,
Al Sears, MD, CNS
References:
1.Galvlin G. “In fight against opioid crisis, targeting prescription drugs is largely futile.” USA Today. Feb. 1, 2019. Accessed on January 27, 2022.
2. Centers for Disease Control and Prevention. “Drug Overdose. www.cdc.gov/drugoverdose/index.html Accessed on January 27, 2022.
3. Huecker, Martin R, et al. “Opioid Addiction.” Nih.gov, StatPearls Publishing, 28 Feb. 2019, www.ncbi.nlm.nih.gov/books/NBK448203/.
4. Rich S, et al. “More than 100 billion pain pills saturated nation over nine years.” www.washingtonpost.com/investigations 2020.
5. “Top Executives of Opioid Company Are Found Guilty of Racketeering.” 2019. New York Times Accessed on January 27, 2022.
6. Goodnough A. “As Tens of Thousands Died, F.D.A. Failed to Police Opioids.” New York Times. Dec 2019. Accessed on January 27, 2022.
7. Rege A. “5 pharmaceutical companies ranked among this year’s fortune 500.” 2017. BeckersHospitalRview.com. Accessed on January 31, 2022.
8. Hurd Y, e al. “Cannabidiol for the reduction of cue-induced craving and anxiety in drug-abstinent individuals with heroin use disorder: a double-blind randomized placebo-controlled trial.” Am J Psych. 2019; 176(11): 911-922.
9. Chan N, et al. “The effects of recreational marijuana legalization and dispensing on opioid mortality.” Economic Inquiry. 2020; 58(2): 589-606.
10. Yamaoka G, et al. Different analgesic effects of adenosine between postoperative and neuropathic pain. J Orthop Sci. 2013;18(1):130-136.
11. De Petrocellis L, et al. Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. Br J Pharmacol. 2011;163(7):1479-1494.
12. De Gregorio D, McLaughlin R, Posa L, et al.Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain. Pain. 2019;160(1):136-150.
13. Abuhasira R, et al. “Epidemiological characteristics, safety and efficacy of medical cannabis in the elderly.” Eur J Intern Med. 2018;49:44-50.
14. Cherniakov I, et al. “Piperine-pro-nanolipospheres as a novel oral delivery system of cannabinoids: Pharmacokinetic evaluation in healthy volunteers in comparison to buccal spray administration.” J Control Release. 2017;266:1-7.
15. Birnbaum AK, et al. “Food effect on pharmacokinetics of cannabidiol oral capsules in adult patients with refractory epilepsy.” Epilepsia. 2019;60(8):1586-1592.